Based on the results of European Organization for Research and Treatment of Cancer
(EORTC) 18991 trial, the US Food and Drug Administration (FDA) approved PEG-interferon …

8504 Background: EORTC 18991 is the largest adjuvant trial ever conducted in stage III
melanoma. It assessed the efficacy and toxicity of long term PEG-IFN vs Observation (Obs.) …

Introduction: Stage III melanoma, also referred to as regional metastatic melanoma, has five-
year survival rates ranging between 40% and 78%. In order to reduce the likelihood of …

Long-Term Results of the Randomized Phase III Trial EORTC 18991 of Adjuvant Therapy With
Pegylated Interferon Alfa-2b Versus Obs Page 1 Long-Term Results of the Randomized Phase III …

Abstract Learning Objectives After completing this course, the reader will be able to:
Describe the setting in which the use of peginterferon-alfa-2b is appropriate for melanoma …

Interferon alfa (IFNα) and pegylated IFNα2b (PegIFNα2b) are the only agents currently
approved for the adjuvant treatment of resected melanoma at high risk of recurrence. Meta …

Despite intensive research and numerous clinical trials on the adjuvant treatment of patients
with high-risk cutaneous melanoma, the issue is still controversial. Early positive results from …

8506b Background: EORTC 18991 is the largest adjuvant trial ever conducted in stage III
melanoma. It assessed the efficacy and toxicity of long-term PEG-IFN vs Observation (Obs.) …

8526 Background: Many randomised trials have evaluated the role of adjuvant interferon-a
(IFN) in high-risk melanoma, some suggesting benefit and others not. To assess the totality …

After more than two decades with interferon alfa-2a and 2b (IFN) as the only approved drugs
in the adjuvant setting for melanoma, new treatment approaches like immune checkpoint …